These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 24164572)
1. Benchmarking in vitro covalent binding burden as a tool to assess potential toxicity caused by nonspecific covalent binding of covalent drugs. Dahal UP; Obach RS; Gilbert AM Chem Res Toxicol; 2013 Nov; 26(11):1739-45. PubMed ID: 24164572 [TBL] [Abstract][Full Text] [Related]
2. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Bauman JN; Kelly JM; Tripathy S; Zhao SX; Lam WW; Kalgutkar AS; Obach RS Chem Res Toxicol; 2009 Feb; 22(2):332-40. PubMed ID: 19161298 [TBL] [Abstract][Full Text] [Related]
3. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Masubuchi N; Makino C; Murayama N Chem Res Toxicol; 2007 Mar; 20(3):455-64. PubMed ID: 17309281 [TBL] [Abstract][Full Text] [Related]
4. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Nakayama S; Atsumi R; Takakusa H; Kobayashi Y; Kurihara A; Nagai Y; Nakai D; Okazaki O Drug Metab Dispos; 2009 Sep; 37(9):1970-7. PubMed ID: 19487250 [TBL] [Abstract][Full Text] [Related]
5. Drug discovery for a new generation of covalent drugs. Kalgutkar AS; Dalvie DK Expert Opin Drug Discov; 2012 Jul; 7(7):561-81. PubMed ID: 22607458 [TBL] [Abstract][Full Text] [Related]
6. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Obach RS; Kalgutkar AS; Soglia JR; Zhao SX Chem Res Toxicol; 2008 Sep; 21(9):1814-22. PubMed ID: 18690722 [TBL] [Abstract][Full Text] [Related]
7. Selection of new chemical entities with decreased potential for adverse drug reactions. Park KB; Dalton-Brown E; Hirst C; Williams DP Eur J Pharmacol; 2006 Nov; 549(1-3):1-8. PubMed ID: 16979156 [TBL] [Abstract][Full Text] [Related]
8. Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. Flanagan ME; Abramite JA; Anderson DP; Aulabaugh A; Dahal UP; Gilbert AM; Li C; Montgomery J; Oppenheimer SR; Ryder T; Schuff BP; Uccello DP; Walker GS; Wu Y; Brown MF; Chen JM; Hayward MM; Noe MC; Obach RS; Philippe L; Shanmugasundaram V; Shapiro MJ; Starr J; Stroh J; Che Y J Med Chem; 2014 Dec; 57(23):10072-9. PubMed ID: 25375838 [TBL] [Abstract][Full Text] [Related]
9. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456 [TBL] [Abstract][Full Text] [Related]
10. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Thompson RA; Isin EM; Li Y; Weaver R; Weidolf L; Wilson I; Claesson A; Page K; Dolgos H; Kenna JG Chem Biol Interact; 2011 Jun; 192(1-2):65-71. PubMed ID: 21074519 [TBL] [Abstract][Full Text] [Related]
11. A semi-automated method for measuring the potential for protein covalent binding in drug discovery. Day SH; Mao A; White R; Schulz-Utermoehl T; Miller R; Beconi MG J Pharmacol Toxicol Methods; 2005; 52(2):278-85. PubMed ID: 16125627 [TBL] [Abstract][Full Text] [Related]
12. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Zhou S; Chan E; Duan W; Huang M; Chen YZ Drug Metab Rev; 2005; 37(1):41-213. PubMed ID: 15747500 [TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione. Takakusa H; Masumoto H; Makino C; Okazaki O; Sudo K Drug Metab Pharmacokinet; 2009; 24(1):100-7. PubMed ID: 19252339 [TBL] [Abstract][Full Text] [Related]